Country
United Kingdom
AstraZeneca Plc is to further evaluate the dosing for its candidate Covid-19 vaccine AZD1222 in light of interim data from trials in the UK and Brazil showing different efficacy rates for different dosing regimens.
Full text available to subscribers only. Click here for information on subscribing to MedNous.